Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer

被引:12
作者
Okamura, Keigo [1 ]
Koike, Hidekazu [1 ]
Sekine, Yoshitaka [1 ]
Matsui, Hiroshi [1 ]
Suzuki, Kazuhiro [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Urol, Gunma 3718511, Japan
关键词
Survivin; Renal cancer; Splice variants; RIBOZYME-MEDIATED INHIBITION; SMALL INTERFERING RNA; IN-VIVO; MELANOMA-CELLS; VARIANTS; APOPTOSIS; CARCINOMAS; DEATH; TRANSFECTION; CHEMOTHERAPY;
D O I
10.1016/j.canep.2009.06.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Survivin has been implicated in inhibition of apoptosis. To date, alternatively spliced isoforms, Survivin-2 alpha, -2B, -Delta Ex3, -3B, have been described. We assessed the effect of survivin gene expression on the proliferation of renal cancer (RCC) cells, and studied the association of survivin and its spliced isoform gene expression levels with the clinical stage of RCC. Methods: Gene expression of survivin and its spliced isoform in RCC cells, Caki-1, were performed by RT-PCR. We knocked down the gene expression of Survivin using small interfering RNA (siRNA), and assessed the cell proliferation by MTS assay. Next, we quantified the gene expression levels of survivin and its isoform in nephrectomy samples using quantitative real-time PCR. Results: In Caki-1 cells, survivin and survivin-2 alpha, -2B were expressed higher than survivin-Delta Ex3. Decrease of survivin gene expression by transfection of siRNA was accompanied by inhibition of the proliferation of Caki-1 cell with 36% decrease in comparison with negative control transfected cells (p < 0.01). In clinical RCC tissues, survivin expression levels in metastatic stage were significantly higher compared with those in distant metastasis stage (M0:M1 = 1:4.81, p = 0.014); survivin 213 gene expression levels in pT3 tumors were associated significantly higher than those in pT1 (pT1:pT3 = 1:4.50, p = 0.043). No significant differences were found in survivin-2 alpha expression levels and the ratio of survivin-2B/survivin gene expression levels among any clinical stages. Conclusion: We first demonstrated the gene expression of survivin-2 alpha in renal cancer cells, and also showed that survivin and its spliced isoforms had associations with renal cancer cell proliferation and distant metastases. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:137 / 141
页数:5
相关论文
共 33 条
[1]  
Altieri DC, 1999, LAB INVEST, V79, P1327
[2]   Survivin splice variants regulate the balance between proliferation and cell death [J].
Caldas, H ;
Jiang, YY ;
Holloway, MP ;
Fangusaro, J ;
Mahotka, C ;
Conway, EM ;
Altura, RA .
ONCOGENE, 2005, 24 (12) :1994-2007
[3]   Survivin 2α:: a novel survivin splice variant expressed in human malignancies [J].
Caldas, Hugo ;
Honsey, Laura E. ;
Altura, Rachel A. .
MOLECULAR CANCER, 2005, 4 (1)
[4]   Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis [J].
Chawla-Sarkar, M ;
Bae, SI ;
Reu, FJ ;
Jacobs, BS ;
Lindner, DJ ;
Borden, EC .
CELL DEATH AND DIFFERENTIATION, 2004, 11 (08) :915-923
[5]  
Dong YY, 2002, ANTICANCER RES, V22, P2377
[6]   Transcriptional expression of survivin and its splice variants in cervical carcinomas [J].
Futakuchi, H. ;
Ueda, M. ;
Kanda, K. ;
Fujino, K. ;
Yamaguchi, H. ;
Noda, S. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (05) :1092-1098
[7]   Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo [J].
Hayashi, N ;
Asano, K ;
Suzuki, H ;
Yamamoto, T ;
Tanigawa, N ;
Egawa, S ;
Manome, Y .
PROSTATE, 2005, 65 (01) :10-19
[8]   High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma [J].
Islam, A ;
Kageyama, H ;
Takada, N ;
Kawamato, T ;
Takayasu, H ;
Isogai, E ;
Ohira, M ;
Hashizume, K ;
Kobayashi, H ;
Kaneko, Y ;
Nakagawara, A .
ONCOGENE, 2000, 19 (05) :617-623
[9]   Short interfering RNAs as a tool for cancer gene therapy [J].
Izquierdo, M .
CANCER GENE THERAPY, 2005, 12 (03) :217-227
[10]  
Kato J, 2001, INT J CANCER, V95, P92